NRx Pharmaceuticals, Inc. (NRXP)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | — | ||
| 10-KLatest | FY-2025 | — | ||
| 10-Q | Q3-2024 | 8-K (2024-08-15) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2025-08-18) · 99.1 | 8-K (2025-05-21) · 99.1 · 99.2 | 8-K (2024-05-16) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2025-03-21) · 99.1 · 99.2 | 8-K (2024-04-02) · 99.1 | ||
| 10-K/A | FY-2024 | |||
| 10-K | FY-2024 | 8-K (2024-11-15) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-08-15) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2025-08-18) · 99.1 | 8-K (2025-05-21) · 99.1 · 99.2 | 8-K (2024-05-16) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2025-03-21) · 99.1 · 99.2 | 8-K (2024-04-02) · 99.1 | ||
| 10-K/A | FY-2023 | |||
| 10-K | FY-2023 | — | ||
| 10-Q | Q3-2023 | 8-K (2023-11-14) · 99.1 | ||
| 10-Q | Q2-2023 | — | ||
| 10-K/A | FY-2022 | |||
| 10-K/A | FY-2022 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Document and Entity Information | ||
| Statements | ||
| Condensed Consolidated Balance Sheets (current Period Unaudited) | — |
|
| Consolidated Balance Sheets | ||
| Condensed Consolidated Balance Sheets (current Period Unaudited) (P) | — |
|
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Condensed Consolidated Statements of Changes In Stockholders' (deficit) (unaudited) | — |
|
| Condensed Consolidated Statements of Changes In Stockholders' Deficit (unaudited) | — |
|
| Condensed Consolidated Statements of Stockholders' (deficit) Equity | ||
| Consolidated Statements of Changes In Stockholders' (deficit) Equity | ||
| Condensed Consolidated Statements of Changes In Stockholders' (deficit) (unaudited) (P) | — |
|
| Condensed Consolidated Statements of Changes In Stockholders' Deficit (unaudited) (P) | — |
|
| Condensed Consolidated Statements of Stockholders' (deficit) Equity (P) | — |
|
| Consolidated Statements of Changes In Stockholders' (deficit) Equity (P) | ||
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Accrued and Other Current Liabilities | ||
| Alvogen Licensing Agreement | ||
| Award Timing Disclosure | — |
|
| Commitments and Contingencies | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Debt | ||
| Equity | ||
| Fair Value Measurements | ||
| Going Concern | — |
|
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Liquidity | ||
| Note 1 | ||
| Note 10 | ||
| Note 11 | ||
| Note 12 | ||
| Note 13 | ||
| Note 14 | ||
| Note 15 | ||
| Note 16 | ||
| Note 17 | ||
| Note 18 | ||
| Note 19 | ||
| Note 2 | ||
| Note 3 | ||
| Note 4 | ||
| Note 5 | ||
| Note 6 | ||
| Note 7 | ||
| Note 8 | ||
| Note 9 | ||
| Organization | ||
| Prepaid Expenses and Other Current Assets | ||
| Related Party Transactions | ||
| Stock-based Compensation | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||